Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan versus placebo in adults with cold agglutinin disease
NL-OMON53572Phase 3Active, not recruiting
- Sponsor
- Sobi
- Start
- Dec 2022
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cold agglutinin disease (CAD) and autoimmune haemolytic anaemia (AIHA) comparing Pegcetacoplan with Placebo (2 arms). Primary endpoint: Response to treatment at Week 24. Started Dec 2022; status: active, not recruiting.
02
Drugs
pegcetacoplan
03
Conditions
cold agglutinin disease (CAD)autoimmune haemolytic anaemia (AIHA)
Beyond the preview
Go deeper on NL-OMON53572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53572.